JP7675009B2 - アレナウイルス感染症の治療のための化合物 - Google Patents
アレナウイルス感染症の治療のための化合物 Download PDFInfo
- Publication number
- JP7675009B2 JP7675009B2 JP2021525159A JP2021525159A JP7675009B2 JP 7675009 B2 JP7675009 B2 JP 7675009B2 JP 2021525159 A JP2021525159 A JP 2021525159A JP 2021525159 A JP2021525159 A JP 2021525159A JP 7675009 B2 JP7675009 B2 JP 7675009B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- compounds
- pharma
- group
- bromo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D249/18—Benzotriazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862776390P | 2018-12-06 | 2018-12-06 | |
| US62/776,390 | 2018-12-06 | ||
| PCT/US2019/064223 WO2020117794A1 (en) | 2018-12-06 | 2019-12-03 | Compounds for the treatment of arenavirus infection |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022509763A JP2022509763A (ja) | 2022-01-24 |
| JP2022509763A5 JP2022509763A5 (https=) | 2022-12-07 |
| JP7675009B2 true JP7675009B2 (ja) | 2025-05-12 |
Family
ID=70975517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021525159A Active JP7675009B2 (ja) | 2018-12-06 | 2019-12-03 | アレナウイルス感染症の治療のための化合物 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP3890731A4 (https=) |
| JP (1) | JP7675009B2 (https=) |
| KR (1) | KR20210106997A (https=) |
| CN (1) | CN113329750B (https=) |
| AR (1) | AR117228A1 (https=) |
| AU (1) | AU2019393784B2 (https=) |
| BR (1) | BR112021010909A2 (https=) |
| EA (1) | EA202191001A1 (https=) |
| MX (2) | MX2021005234A (https=) |
| WO (1) | WO2020117794A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116217490B (zh) * | 2023-02-03 | 2025-09-26 | 中国人民解放军军事科学院军事医学研究院 | 一种苯并咪唑类化合物及其制备方法和应用 |
| EP4434972A1 (en) * | 2023-03-22 | 2024-09-25 | Eberhard-Karls-Universität Tübingen | Atm kinase inhibitors |
| WO2025137345A1 (en) * | 2023-12-20 | 2025-06-26 | Arisan Therapeutics Inc. | Crystalline forms of an imidazopyridine derivative |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018013430A2 (en) | 2016-07-12 | 2018-01-18 | Arisan Therapeutics Inc. | Heterocyclic compounds for the treatment of arenavirus infection |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2293638T3 (es) * | 1994-03-25 | 2008-03-16 | Isotechnika, Inc. | Mejora de la eficacia de farmacos por deuteracion. |
| WO2012065297A1 (en) * | 2010-11-16 | 2012-05-24 | Impact Therapeutics, Inc. | 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF |
| AP3675A (en) * | 2012-02-17 | 2016-04-15 | Kineta Four Llc | Antiviral drugs for treatment of arenavirus infection |
| US9688680B2 (en) | 2014-08-04 | 2017-06-27 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
-
2019
- 2019-12-02 AR ARP190103517A patent/AR117228A1/es unknown
- 2019-12-03 MX MX2021005234A patent/MX2021005234A/es unknown
- 2019-12-03 CN CN201980080594.2A patent/CN113329750B/zh active Active
- 2019-12-03 EA EA202191001A patent/EA202191001A1/ru unknown
- 2019-12-03 EP EP19892030.8A patent/EP3890731A4/en active Pending
- 2019-12-03 WO PCT/US2019/064223 patent/WO2020117794A1/en not_active Ceased
- 2019-12-03 AU AU2019393784A patent/AU2019393784B2/en active Active
- 2019-12-03 JP JP2021525159A patent/JP7675009B2/ja active Active
- 2019-12-03 BR BR112021010909-9A patent/BR112021010909A2/pt unknown
- 2019-12-03 KR KR1020217017726A patent/KR20210106997A/ko not_active Ceased
-
2021
- 2021-05-04 MX MX2024013042A patent/MX2024013042A/es unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018013430A2 (en) | 2016-07-12 | 2018-01-18 | Arisan Therapeutics Inc. | Heterocyclic compounds for the treatment of arenavirus infection |
Non-Patent Citations (2)
| Title |
|---|
| Chemistry & Industry，2009年，9 March，24-26 |
| Glob J Pharmaceu Sci，2017年，1(4)，1-11 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3890731A4 (en) | 2022-08-17 |
| MX2021005234A (es) | 2021-08-11 |
| AU2019393784B2 (en) | 2025-06-12 |
| JP2022509763A (ja) | 2022-01-24 |
| MX2024013042A (es) | 2024-12-06 |
| CA3118765A1 (en) | 2020-06-11 |
| EA202191001A1 (ru) | 2021-08-16 |
| CN113329750B (zh) | 2025-10-17 |
| AU2019393784A1 (en) | 2021-05-27 |
| EP3890731A1 (en) | 2021-10-13 |
| WO2020117794A1 (en) | 2020-06-11 |
| CN113329750A (zh) | 2021-08-31 |
| BR112021010909A2 (pt) | 2021-08-24 |
| KR20210106997A (ko) | 2021-08-31 |
| AR117228A1 (es) | 2021-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11352328B2 (en) | Heterocyclic compounds for the treatment of arenavirus | |
| Pan et al. | Development of benzimidazole derivatives to inhibit HIV-1 replication through protecting APOBEC3G protein | |
| AU2018331172B2 (en) | Influenza virus replication inhibitor and use thereof | |
| CN112940010B (zh) | 经取代的多环性吡啶酮衍生物及其前药 | |
| US12240857B2 (en) | Adamantane derivatives for the treatment of filovirus infection | |
| WO2019018185A1 (en) | ENANTIOMERICALLY PURE ADAMATANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTIONS | |
| EP3953361A1 (en) | Compounds and methods for the treatment of covid-19 | |
| JP7675009B2 (ja) | アレナウイルス感染症の治療のための化合物 | |
| RS60350B1 (sr) | Kombinovani tretman agonistom tlr7 i inhibitorom sklopa hbv kapsida | |
| JP2022511819A (ja) | ヘテロアリールジヒドロピリミジン誘導体及びｂ型肝炎感染症を治療する方法 | |
| BR112014007134B1 (pt) | Usos de um composto da fórmula (b), compostos, composição farmacêutica, método de preparação do composto e uso do composto para fabricação de um medicamento para tratar ou prevenir infecções flavivirais | |
| BR112020008762A2 (pt) | indol-2-carboxamidas amino-tiazol substituídas altamente ativas inovadoras ativas contra o vírus da hepatite b (hbv) | |
| TW202035412A (zh) | 雜芳基二氫嘧啶衍生物和治療ｂ型肝炎感染之方法 | |
| JP2013512246A (ja) | ウイルス疾患治療に有用な縮合型三環式化合物およびその誘導体 | |
| US12358897B2 (en) | Compounds and method of treating COVID-19 | |
| JP2018515489A (ja) | ヒストンデアセチラーゼ阻害薬及び組成物並びにそれらの使用の方法 | |
| JP2025507472A (ja) | ケトアミド系誘導体及びその製薬における使用 | |
| US12419865B2 (en) | Compounds for the treatment of arenavirus infection | |
| CA3118765C (en) | Compounds for the treatment of arenavirus infection | |
| EA044865B1 (ru) | Соединения для лечения аренавирусной инфекции | |
| WO2021262426A9 (en) | Adamantane amides and thioamides for the treatment of ebolavirus infection | |
| OA20266A (https=) | ||
| HK40079963B (zh) | 含吡啶酮稠环类衍生物抑制剂、其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A525 Effective date: 20210706 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221128 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221128 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20231109 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231212 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240308 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20240308 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240402 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240513 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240903 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20241122 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20250124 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250227 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250415 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250425 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7675009 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |